Healthcare Business - Page 2

Merrimack Discontinues Cancer Study Amidst Layoffs

Posted: April 5, 2019 at 9:20 am

Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) has announced that it will be discontinuing one of its cancer drugs, as well as conducting layoffs. Specifically, the firm is discontinuing MM-310 for the ...
Read Full Story »

PTSD Treatment Looked at for Fibromyalgia

Posted: April 4, 2019 at 10:40 am

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares jumped on Monday after the firm announced the expansion of its late-stage post-traumatic stress disorder (PTSD) treatment. Specifically, the firm announced the expansion ...
Read Full Story »

Drug Candidate Makes Big Strides in the Treatment of Parkinson’s Disease Cognitive Impairment

Posted: April 3, 2019 at 11:10 am

Biopharmaceutical company Aptinyx Inc. (NASDAQ: APTX) has announced positive preclinical data on its novel NMDA receptor modulator, NYX-458, demonstrating reversal of cognitive deficits in a nonhuman primate model of ...
Read Full Story »

The Search for Next-Generation Medical Cannabis for PTSD, Chronic Pain and Cancer

Posted: April 3, 2019 at 10:25 am

Agricultural engineering company Evogene Ltd. (NASDAQ: EVGN) has announced the establishment of a new subsidiary, called Canonic, to develop next-generation medical cannabis products. Keep in mind that while Evogene may ...
Read Full Story »

Opioid Prescriptions Are Down, So Why Are They Still Killing Americans?

Posted: April 2, 2019 at 2:18 pm

Between 2006 and 2017, U.S. retail pharmacies filled 233.7 million prescriptions for opioids. In 2006, opioid prescriptions in 14 states met or exceeded a medically determined high dosage level. That ...
Read Full Story »

What’s Next for Sangamo After This Hemophilia Study

Posted: April 2, 2019 at 11:40 am

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer Inc. (NYSE: PFE). The Phase 1/2 ...
Read Full Story »

How Apyx Medical Was Crushed by the FDA

Posted: April 2, 2019 at 10:45 am

Apyx Medical Corp. (NASDAQ: APYX) shares dropped sharply on Tuesday after the company announced that it has voluntarily withdrawn its application for premarket notification 510(k) regulatory clearance of J-Plasma/Renuvion for ...
Read Full Story »

What’s Next for Tricida’s Chronic Kidney Disease Treatment

Posted: March 28, 2019 at 12:25 pm

After Tricida Inc. (NASDAQ: TCDA) announced results from its chronic kidney disease (CKD) trial, its shares jumped on Thursday. Specifically, the results come from TRCA-301 (veverimer), in 196 CKD patients ...
Read Full Story »

Can Proteon Therapeutics Come Back From This Chronic Kidney Disease Study?

Posted: March 28, 2019 at 11:10 am

Proteon Therapeutics Inc. (NASDAQ: PRTO) shares were absolutely crushed on Thursday after the firm announced results from its late-stage trial in patients with chronic kidney disease (CKD). Specifically, the Phase ...
Read Full Story »

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

Posted: March 27, 2019 at 3:55 pm

Shares of drug giant Pfizer Inc. (NYSE: PFE) have lagged rival Merck & Co. Inc. (NYSE: PFE). The gain of 23% for Pfizer from this time a year ago is ...
Read Full Story »

Why the Market Is Punishing Centene Over Its Planned WellCare Health Plans Acquisition

Posted: March 27, 2019 at 12:55 pm

Investors frequently win when they invest in a company that is being acquired, and sometimes they even get a bump in owning shares of the company acquisition. And some mergers ...
Read Full Story »

What’s Next for Axsome Therapeutics After This FDA Approval

Posted: March 27, 2019 at 10:45 am

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares jumped on Wednesday after the firm said it received an update from the U.S. Food and Drug Administration (FDA). Essentially, the agency granted Breakthrough ...
Read Full Story »

Major Pharma Sees a Few Wild Swings in Short Interest

Posted: March 27, 2019 at 8:50 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Biotechs Scare Off Short Sellers

Posted: March 27, 2019 at 8:30 am

The short interest data are out for the most recent settlement date, March 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Will Pacemakers and Other Medical Implants Be Hacked?

Posted: March 25, 2019 at 1:45 pm

Last October, the U.S. Food and Drug Administration (FDA) issued a call for comments to new guidance from the agency on the cybersecurity vulnerabilities of networked medical devices that can ...
Read Full Story »